Brought to you by 
Illumina buys Solexa in stock-for-stock transaction
03 Aug 2007
Executive Summary
Expanding into next-generation sequencing, Illumina has agreed to acquire fellow genomics analysis company Solexa in a stock swap valued at $600mm, or about $14 per outstanding Solexa share (a 44% premium based on the 10-day pre-announcement average). Illumina will also buy $50mm in newly issued Solexa shares (5.15mm at the market price of $9.70).
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Illumina buys Solexa in stock-for-stock transaction
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice